From TGaS Advisors' Press Room
E. Norriton, Penn. and Melrose, UK. 9.14.17. Credible forecasts create hundreds of millions of dollars of additional value for biopharma companies and investors, according to research by TGaS Advisors, a benchmarking and advisory services firm for life sciences commercial operations. Understanding asset evaluation is considered a critical element of the drug commercialization process and a fundamental component underpinning global commercial strategy development. To enable life sciences companies to maximize both their asset development and strategic launch plans, TGaS has formed a partnership with Mirador Analytics, Ltd., a UK company with advanced global forecasting capabilities. The partnership makes asset forecasting and benchmarking available as a holistic service offering to global biopharmaceutical organizations.
Asset Evaluation Online Tool Launch Mention, BioInformant Research
The launch of our new online version of the Asset Evaluation Tool has been shared via BioInformant Research.
BioInformant is the first and currently only market research firm specializing in the stem cell industry.
You can read the article on their website by clicking the link here: BioInformant: Asset Evaluation Tool Article
For further detail of the Asset Evaluation Online Tool, please use the "Contact Us" page or email directly via email@example.com
Revolutionizing Asset Evaluation
We’re delighted to let you know that we’ve launched an online version of our prevalence-based Asset Evaluation Tool.
If you’re engaged in New Product Planning, Drug Development, Launch Planning, Portfolio Prioritization, Life Cycle Management or working towards a specific transaction (e.g. license and/or investment), I’d love to chat with you and explore how the Asset Evaluation Tool could support you through these processes.
With online access via an annual license, unlimited remote asset forecasting is now available, providing you with greater forecasting freedom and flexibility. Mirador Analytics’ Asset Evaluation Tool is perfectly positioned to assist you with strategic decision making, optimizing value and assessing risk. Should you require assistance with inputs into the Asset Evaluation Tool, our experienced consulting team can support here. If required, we can also build a bespoke Forecasting Tool to match your company’s precise specifications.
Drug development and commercialization is an uncertain process. As a commercialization catalyst, Mirador Analytics helps foster the drug innovation process and provides drug commercialization assessment and launch planning services to biopharma SMEs around the world. With this in mind, alongside our Asset Evaluation services, we can also assist with Portfolio Prioritization, Life Cycle Management and Business Development Transactional Services.
Mirador Analytics is unique in comparison to other analytics and consulting organizations. We have extensive experience in the pharmaceutical sector and our team members have worked in similar senior-level roles to our clients. Alongside this, by combining both analytical and consultancy services we deliver relevant industry-specific outputs during every interaction with you.
To learn more about the Asset Evaluation Tool or to set up a complimentary trial, please get in touch via the contact us page.
Check out our news section for; our previous articles, events we are attending and other Mirador Analytics relevant updates.